Encephalopathy | A Pipeline Analysis Report 2018 | Technavio

Technavio has published a new report on the drug development pipeline for encephalopathy, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the encephalopathy market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat encephalopathy.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Encephalopathy: Market overview

Encephalopathy is a common brain disease or malfunction of the brain. It is a syndrome that is characterized by multiple brain disorders. It may be caused by metabolic or mitochondrial dysfunction, infectious agents (bacteria, virus, or prion), increased pressure in the skull, prolonged exposure to toxins, chronic progressive trauma, or lack of oxygen or poor nutrition of blood flow to the brain. It differs from person to person and can be both temporary and permanent. Furthermore, bacterial infection, liver damage, brain anoxia, and kidney failure are the common causes of encephalopathy.

According to a senior market research analyst at Technavio, “The disease can develop at any age and can be present at the time of birth or may never be cured. According to a renowned research, 30% to 45% of people with liver cirrhosis have hepatic encephalopathy. As a result, with rising incidences of the disease, the drug development for encephalopathy is likely to increase considerably in the forthcoming years.”

Encephalopathy: Segmentation analysis

This pipeline analysis report segments the encephalopathy market based on therapies employed (monotherapy and combination therapy), RoA (oral, intravenous, parenteral, transdermal, intravenous/subcutaneous, and intranasal), therapeutic modality (small molecule, stem cell therapy, biological, peptide, monoclonal antibody, oligonucleotides, antibody, microbiome and hormone), targets (serotonin receptor, GABA A receptor, ammonia, KCNQ potassium channel, JCV, CDKL5, stem cells, and others), MoA (serotonin receptor modulator, GABA A receptor modulator, ammonia scavengers, KCNQ potassium channel agonist, JCV inhibition, CDKL5 inhibitor, cell replacements, and others), geographical segmentation (US, Europe, Australia, New Zealand, Canada, and Hong Kong) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, more than 73% of the molecules that are being investigated for the treatment of encephalopathy are small molecule.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has published a new report on the drug development pipeline for encephalopathy, including a detailed study of the pipeline molecules.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com